Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Return on Sales (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Return on Sales over the past 3 years, most recently at 8.71% for Q4 2025.

  • Quarterly results put Return on Sales at 8.71% for Q4 2025, up 11.0% from a year ago — trailing twelve months through Dec 2025 was 9.32% (up 428.0% YoY), and the annual figure for FY2025 was 9.28%, up 438.0%.
  • Return on Sales for Q4 2025 was 8.71% at Tonix Pharmaceuticals Holding, up from 9.68% in the prior quarter.
  • Over the last five years, Return on Sales for TNXP hit a ceiling of 5.61% in Q3 2024 and a floor of 35.02% in Q2 2024.
  • Median Return on Sales over the past 3 years was 8.6% (2024), compared with a mean of 10.83%.
  • Biggest five-year swings in Return on Sales: tumbled -2683bps in 2024 and later soared 2133bps in 2025.
  • Tonix Pharmaceuticals Holding's Return on Sales stood at 7.23% in 2023, then dropped by -22bps to 8.81% in 2024, then rose by 1bps to 8.71% in 2025.
  • The last three reported values for Return on Sales were 8.71% (Q4 2025), 9.68% (Q3 2025), and 13.69% (Q2 2025) per Business Quant data.